Loading...
•
Sep 30, 2021
Alnylam Q3 2021 Earnings Report
Alnylam's third quarter performance was driven by ONPATTRO's strength and the continued rollouts of GIVLAARI and OXLUMO. The company also reported positive topline results from the HELIOS-A Phase 3 study of vutrisiran.
Key Takeaways
Alnylam Pharmaceuticals reported a combined net product revenue of $167 million for ONPATTRO, GIVLAARI, and OXLUMO in Q3 2021. The company reiterated its 2021 financial guidance, expecting combined net product revenues of $640-$665 million.
Achieved $167 million in combined net product revenues for ONPATTRO, GIVLAARI, and OXLUMO in Q3 2021.
Reported positive topline 18-month results from the HELIOS-A Phase 3 study of Vutrisiran in hATTR Amyloidosis Patients with Polyneuropathy.
Completed enrollment ahead of schedule in the HELIOS-B Phase 3 Study of Vutrisiran in ATTR Amyloidosis Patients with Cardiomyopathy.
Reiterated 2021 financial guidance, including combined net product revenues of $640-$665 million.
Revenue by Segment
Forward Guidance
Alnylam reiterated its 2021 financial guidance.
Positive Outlook
- Combined net product revenues for ONPATTRO, GIVLAARI and OXLUMO are expected to be between $640 million and $665 million.
- Net revenues from collaborations and royalties are expected to be between $150 million and $200 million.
- Full results from the ILLUMINATE-C Phase 3 study of lumasiran at the American Society of Nephrology (ASN) Kidney Week 2021, being held November 2-7, 2021 in San Diego, California.
- Additional clinical results from the Phase 1 study of zilebesiran, an investigational RNAi therapeutic in development for the treatment of hypertension, at the American Heart Association (AHA) Scientific Sessions, being held November 13-15, 2021 in Boston, Massachusetts.
- Full 18-month endpoint and safety results from the HELIOS-A Phase 3 study of vutrisiran in early 2022.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...